CPT® Code 81536

Official Description

Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)

Common Language Description

The CPT® Code 81536 pertains to a specialized laboratory test utilized in the field of oncology, specifically focusing on gynecologic tumors. This procedure involves the culture of live tumor cells, which are obtained from a gynecologic tumor specimen. The primary objective of this test is to evaluate the response of these tumor cells to various chemotherapeutic agents. The assessment is conducted using a technique that incorporates DAPI (4’, 6-diamidino-2-phenylindole) staining and morphological analysis. DAPI is a fluorescent stain that selectively binds to A-T-rich regions of DNA, allowing for a clear distinction between live and dead cells. This characteristic is crucial, as it enables the laboratory to determine the viability of the tumor cells after exposure to chemotherapeutic drugs. The test is designed to identify the most effective chemotherapeutic regimens tailored to the unique characteristics of the tumor, thereby enhancing treatment precision. The results are reported as a drug response score, which is derived from a predictive algorithm that analyzes the survival rates of the tumor cells in response to the administered drugs. It is important to note that CPT® Code 81536 is used in conjunction with CPT® Code 81535, which covers the first single drug or drug combination tested. Code 81536 serves as an adjunct code for each additional single drug or drug combination evaluated, thereby facilitating a comprehensive assessment of the tumor's response to multiple therapeutic options.

1. Indications

The procedure associated with CPT® Code 81536 is indicated for the evaluation of gynecologic tumors where there is a need to assess the effectiveness of chemotherapeutic agents. This test is particularly relevant in the following scenarios:

Assessment of Chemotherapy Response This test is performed to determine how well a specific chemotherapeutic agent or combination of agents can inhibit the growth of live tumor cells derived from a gynecologic tumor.
Personalized Treatment Planning The results from this assay can guide oncologists in selecting the most appropriate chemotherapy regimen tailored to the individual tumor's characteristics, potentially improving treatment outcomes.
Evaluation of Drug Resistance The test may be utilized to identify potential drug resistance in tumor cells, allowing for adjustments in treatment strategies to enhance efficacy.

2. Procedure

The procedure for CPT® Code 81536 involves several critical steps to ensure accurate assessment of the tumor cells' response to chemotherapeutic agents. Each step is outlined as follows:

Step 1: Tumor Cell Isolation Live tumor cells are isolated from a gynecologic tumor specimen. This process involves careful handling to maintain cell viability, ensuring that the cells remain alive for subsequent testing.
Step 2: Cell Culture Establishment The isolated tumor cells are then established in an in vitro culture medium. This environment is optimized to support the growth and maintenance of the live cells, allowing them to proliferate under controlled conditions.
Step 3: Drug Exposure The cultured tumor cells are incubated with one or more chemotherapeutic agents for a specified duration. This exposure is critical for assessing how the cells respond to the drugs, simulating the conditions they would encounter in a clinical treatment setting.
Step 4: DAPI Staining After the incubation period, the cells are stained with DAPI. This fluorescent stain binds to the DNA of the cells, allowing for differentiation between live and dead cells based on the intensity of the fluorescence observed.
Step 5: Morphological Assessment The stained cells are then analyzed morphologically to evaluate their viability. The assessment focuses on the survival of the cells post-exposure to the chemotherapeutic agents, providing insights into the effectiveness of the drugs tested.
Step 6: Reporting of Results Finally, the results are compiled and reported as a drug response score, which is derived from a predictive algorithm that interprets the data collected during the procedure. This score aids in determining the most effective treatment options for the patient.

3. Post-Procedure

Post-procedure care following the testing associated with CPT® Code 81536 typically involves the interpretation of the drug response score by the healthcare provider. The results will guide the oncologist in making informed decisions regarding the patient's chemotherapy regimen. There are no specific recovery protocols required for the patient, as this is a laboratory-based procedure rather than a surgical intervention. However, it is essential for the healthcare team to discuss the findings with the patient, including the implications for treatment and any potential adjustments to the chemotherapy plan based on the test results. Continuous monitoring and follow-up may be necessary to assess the patient's response to the selected treatment regimen.

Short Descr	ONCOLOGY GYNECOLOGIC
Medium Descr	ONCOLOGY GYNE LIVE TUM CELL CLTR&CHEMO RESP ADD
Long Descr	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
CLIA Waived (QW)	No
APC Status Indicator	Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	11

This is an add-on code that must be used in conjunction with one of these primary codes.

81535

Female Edit MPFS Status: Statutory exclusion (from MPFS, may be paid under other methodologies) APC A Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination